Atopix Therapeutics Limited, an Oxford, UK-based biopharmaceutical company developing innovative CRTH2 antagonists for Th2-mediated diseases including atopic dermatitis and severe asthma, received a £3.25M term loan.
The Silicon Valley Bank provided the debt financing.
The company intends to use the funds for its phase two clinical studies.
Led by Tim Edwards, Executive Chairman, Atopix Therapeutics is a clinical-stage, biopharmaceutical company focused on developing a novel class of medicines to treat TH2-mediated disease indications, including atopic dermatitis and severe asthma.
Investors included SROne, Wellington Partners and SV Life Sciences.